High-CBD Anxiety Treatment: Why Four-Week Improvement Does Not Isolate CBD

Fourteen patients reported less anxiety after four weeks of a high-CBD cannabis-derived preparation, with improvements on selected cognitive measures. The open-label study supplies preliminary human evidence, but cannot isolate CBD from expectancy, repeated testing or other constituents.

The preparation was not pure CBD

Patients used a full-spectrum sublingual solution three times daily. The supplied formulation contained 9.97 mg/mL CBD and 0.23 mg/mL THC. The intended daily exposure was approximately 30 mg CBD and less than 1 mg THC.

Describing this as a trial of isolated CBD would change the intervention. Absence of reported intoxication does not establish absence of THC exposure.

Clinical and cognitive outcomes

Anxiety ratings improved significantly relative to baseline. The investigators also reported improvements in mood, sleep, quality of life and executive-function measures. There were no reported serious adverse events or intoxication; minor effects included sleepiness or fatigue.

The cognitive battery was repeated at baseline and week four. Without an appropriate blinded control group in this stage, practice and changes in anxiety itself remain plausible contributors to improved test performance.

What remains uncertain

This was a small, short, open-label stage, not the definitive placebo-controlled stage described by the authors. A response definition based on a specified percentage reduction is also not synonymous with complete remission.

The paper disclosed outside cannabis-related research and advisory interests. Those disclosures should accompany assessment of the preliminary findings.

For a functional assessment, the study cannot certify an individual’s driving or establish a blood concentration indicating benefit. Its central lesson is that clinical improvement, a cognitive score and the concentration of an individual cannabinoid answer different questions.

Related analysis

See our analysis of formulation-specific cannabinoid exposure.

Primary research

Mary Kathryn Dahlgren and colleagues. Clinical and cognitive improvement following full-spectrum, high-cannabidiol treatment for anxiety: open-label data from a two-stage, phase 2 clinical trial. Communications Medicine, 2022. DOI: 10.1038/s43856-022-00202-8.

Spread the love


The National Black Lawyers

top 40 lawyers

civil trial law

Lawyers of Distinction

Loading...

Recent Blog Articles

A Cannabis Trial’s Smoking-Procedure Change Was Not a Randomized Safety Comparison

A cannabis driving trial reported fewer adverse events after switching from paced smoking to smoking to a desired effect. That observation does not establish the size of a causal safety benefit. The trial randomized cannabis-potency conditions; the smoking procedure changed during the study because the initial procedure was poorly tolerated….

Spread the love

Read Article: A Cannabis Trial’s Smoking-Procedure Change Was Not a Randomized Safety Comparison

THC Measured Per Forehead Sweat Pad Cannot Be Converted Into a Blood Concentration

A result expressed as nanograms of THC per sweat pad measures the amount recovered from that pad. It does not provide a blood concentration. A study involving drivers investigated in Italy illustrates why collection units, confirmation and participant selection must remain visible when interpreting forehead-sweat evidence. The collection sampled the…

Spread the love

Read Article: THC Measured Per Forehead Sweat Pad Cannot Be Converted Into a Blood Concentration

An Unidentified Serum Compound Does Not Justify Subtracting 14.6% From Every THC-COOH Result

A serum study found a compound that could interfere with THC-COOH measurement, but its reported median relative abundance was not a universal measurement error. The finding supports checking a laboratory’s separation and identification procedures. It does not justify subtracting 14.6% from every reported cannabis-metabolite result. The problem appeared in authentic…

Spread the love

Read Article: An Unidentified Serum Compound Does Not Justify Subtracting 14.6% From Every THC-COOH Result

Speak with an expert today!

Contact the offices of Okorie Okorocha for professional and reliable advice which you can trust.

Call (424) 363-3347 Contact Us